Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423514 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29386346 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL7423417 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL2313063 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13163967 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29511158 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL8350965 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13636676 | 0.91 | MDM4 (0.51) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL18358965 | 0.91 | CASP3 (0.55) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29477062 | 0.90 | MDM4 (0.55) | CASP3MDM4TP53MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | Technische Universität München (DE) | 2026-03-17 | — | — | US | disclosed |
| EP-4704874-A2 | MOLECULES AND METHODS OF USE THEREOF | Woolwich Sciences LLC (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4508235-A2 | PAPB AS A BIMOIETY-DEPENDENT THIOETHER INSTALLATION TOOL | University of Utah Research Foundation (US) | 2025-02-19 | — | — | EP | disclosed |
| WO-2025013923-A1 | METHOD FOR LABELING ISOASPARTIC ACID (Lβ-ASPARTIC ACID) RESIDUE | 国立研究開発法人 産業技術総合研究所 | 2025-01-16 | — | — | WO | disclosed |
| WO-2024226545-A2 | MOLECULES AND METHODS OF USE THEREOF | WOOLWICH SCIENCES LLC (US) | 2024-10-31 | — | — | WO | disclosed |
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-09-26 | — | — | US | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| EP-4337270-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2024-03-20 | — | — | EP | disclosed |
| US-20240011979-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS INC. (KR) | 2024-01-11 | — | — | US | disclosed |
| CN-117320759-A | Radiopharmaceutical somatostatin receptor ligands and precursors thereof | 慕尼黑工业大学 | 2023-12-29 | — | — | CN | disclosed |
| CN-116829949-A | Compositions for detecting or measuring analytes | 伯蒂斯有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2023075435-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | 주식회사 베르티스 | 2023-05-04 | — | — | WO | disclosed |
| US-11629201-B2 | PSMA-binding agents and uses thereof | ITM Isotope Technologies Munich SE (DE) | 2023-04-18 | — | — | US | disclosed |
| CN-110740757-B | Novel PSMA-binding agents and uses thereof | 同位素技术慕尼黑公司 | 2023-04-04 | — | — | CN | disclosed |
| WO-2022238553-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-11-17 | — | — | WO | disclosed |
| US-20220283131-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTES | BERTIS CO., LTD. (KR) | 2022-09-08 | — | — | US | disclosed |
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | UNIVERSITY OF HAWAII (US) | 2022-04-12 | — | — | US | disclosed |
| US-20220096669-A1 | SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF | Technische Universität München (DE) | 2022-03-31 | — | — | US | disclosed |
| WO-2022050529-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | ㈜베르티스 | 2022-03-10 | — | — | WO | disclosed |
| US-20220024882-A1 | NOVEL TUMOR ANTIGEN BINDING AGENTS AND USES THEREOF | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11299480-B2 | 2-arylsulfonamido-N-arylacetamide derivatized STAT3 inhibitors | STAT3, JAK2, STAT5A | CASP3 1275/4885MDM4 3843/4885TP53 33/4885 |
| US-20220096669-A1 | SILICON-FLUORIDE ACCEPTOR SUBSTITUTED RADIOPHARMACEUTICALS AND PRECURSORS THEREOF | FOLH1, KLK3, FRS2 | CASP3 4055/4885MDM4 3612/4885TP53 458/4885 |
| US-11629201-B2 | PSMA-binding agents and uses thereof | FOLH1, PSMA3, PSMA2 | CASP3 3020/4885MDM4 513/4885TP53 205/4885 |
| US-20220024882-A1 | NOVEL TUMOR ANTIGEN BINDING AGENTS AND USES THEREOF | CD74, MICA, CD2BP2 | CASP3 4252/4885MDM4 1065/4885TP53 4/4885 |
| US-20240317780-A1 | RADIOPHARMACEUTICAL SOMATOSTATIN RECEPTOR LIGANDS AND PRECURSORS THEREOF | SSTR1, SSTR3, SSTR4 | CASP3 4196/4885MDM4 1685/4885TP53 455/4885 |
| US-12576169-B2 | Silicon-fluoride acceptor substituted radiopharmaceuticals and precursors thereof | KLK3, FOLH1, SLC7A1 | CASP3 3478/4885MDM4 4308/4885TP53 493/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.